Sign Up Today and Learn More About Colossal Biosciences Stock
Invest in or calculate the value of your shares in Colossal Biosciences or other pre-IPO companies through EquityZen's platform.
Colossal Biosciences Stock
Colossal is a bioscience and genetic engineering company focused on de-extinction of past species.
About Colossal Biosciences Stock
Founded
2021
Headquarters
Dallas, TX, US
Total Funding
257M
Industries
Science and Engineering, Health Care, Biotechnology
Colossal Biosciences is a genetic engineering company attempting to bring back extinct species and preserve threatened ones. The company leverages CRISPR/Cas9 technology and software tools to advance genomic science. Colossal is actively pursing the de-extinction of the woolly mammoth, the Tasmanian tiger, and the dodo with the mission is to restore Earth to a healthier state.
Colossal Biosciences was founded in 2021 and is headquartered in Dallas Texas. Notable investors include At One Ventures, Thomas Tull, Draper Associates and U.S. Innovative Technology.Â
Colossal Biosciences Press Mentions
Stay in the know about the latest news on Colossal Biosciences
Scientists Are Inching Closer to Bringing Back the Woolly Mammoth
wired • Jul 24, 2024
Scientists say they’re closer to reviving mammoths. What could go wrong?
washingtonpost • Jul 24, 2024
Scientists inch forward in efforts to resurrect an extinct giant
cnn • Jul 24, 2024
Colossal Biosciences’ 2028 goal: Bringing back the woolly mammoth
labiotech • Jul 24, 2024
Colossal Biosciences has made headlines as the de-extinction startup primed to bring back the woolly mammoth. Here’s how the business model actually works.
fortune • Jul 24, 2024
Colossal Biosciences Management
Leadership team at Colossal Biosciences
Co-Founder & CEO
Ben Lamm
Co-Founder & Lead Genetics Advisor
George Church
Join now and verify your accreditation status to gain access to:
- Colossal Biosciences current valuation
- Colossal Biosciences stock price
- Available deals in Colossal Biosciences and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Colossal Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Colossal Biosciences through EquityZen funds. These investments are made available by existing Colossal Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Colossal Biosciences stock?
Shareholders can sell their Colossal Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
